GLOW Blend (BPC-157 + GHK-Cu + TB-500)

BPC-157 Regulatory Notice: BPC-157 is currently under FDA Pharmacy Compounding Advisory Committee (PCAC) review for potential designation as a bulk substance prohibited from compounding under FDCA Section 503A/503B. Regulatory status may evolve. This vial is a research reagent only.

What is GLOW Blend (BPC-157 + GHK-Cu + TB-500)?

GLOW Blend is a triple-peptide research formulation co-formulating three mechanistically distinct tissue repair and regenerative research compounds: BPC-157 (Body Protection Compound 157, 10mg), GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper complex, 50mg), and TB-500 (Thymosin Beta-4 fragment 17–23, 10mg). Each component investigates an independent molecular mechanism: BPC-157 modulates the VEGFR2-Akt-eNOS angiogenic and FAK-paxillin cytoprotective signalling axis; GHK-Cu operates through Cu²⁺-mediated integrin receptor activation, MMP-2 modulation, and broad transcriptomic reprogramming of collagen synthesis and antioxidant pathway genes; TB-500 drives directional cell migration via G-actin sequestration and integrin-linked kinase (ILK) pathway activation. The three non-overlapping receptor mechanisms make GLOW Blend relevant to multi-pathway tissue repair biology, comparative angiogenesis pathway research, and extracellular matrix remodelling investigation in preclinical cell and animal model systems.

This compound is not approved by the U.S. FDA for human or veterinary use. Intended for laboratory and research purposes only. Not a dietary supplement or consumer product. BPC-157 is under FDA PCAC review. This is a research reagent only.

Chemical Properties

How Does GLOW Blend Work?

BPC-157 → VEGFR2 / eNOS / FAK-Paxillin: BPC-157 (GEPPPGKPADDAGLV) is a synthetic 15-amino acid pentadecapeptide derived from a gastric juice protein sequence. In preclinical cell models, BPC-157 has been documented to: (1) upregulate VEGFR2 (vascular endothelial growth factor receptor 2) expression on endothelial cells and activate the VEGFR2-Akt-eNOS signalling cascade, increasing nitric oxide (NO) production and endothelial proliferation; (2) activate focal adhesion kinase (FAK) and paxillin, facilitating directional migration of fibroblasts, repair cells, and endothelial cells to injury sites in rodent organ injury models. BPC-157's resistance to gastric acid degradation and absence of a defined systemic receptor distinguish its pharmacological profile from classical growth factor or receptor agonist compounds in the tissue repair research landscape.

GHK-Cu → Cu²⁺-Mediated Gene Expression / MMP-2 Modulation / Collagen Synthesis: GHK (Glycyl-L-Histidyl-L-Lysine) coordinates Cu²⁺ with high affinity via the imidazole nitrogen of histidine and the terminal amino groups of glycine. At 1–10 nM concentrations in fibroblast cell cultures, GHK-Cu has been documented to: (1) stimulate synthesis of type I and III collagen, dermatan sulfate, chondroitin sulfate, and the proteoglycan decorin (Pickart et al. 2015, PMID 26236730); (2) stimulate MMP-2 (matrix metalloproteinase-2) gene expression by fibroblasts while modulating TIMP (tissue inhibitor of metalloproteinase) balance, enabling ECM remodelling without fibrotic overdeposition (Siméon et al. 2000, PMID 11045606); (3) activate integrin-linked kinase (ILK) on cell membranes, driving PI3K/Akt and MAPK downstream signalling; (4) modulate expression of over 4,000 human genes with ≥50% expression change in gene expression array studies, including significant enrichment in collagen synthesis, antioxidant response, DNA repair, and anti-inflammatory pathway gene clusters (Pickart & Margolina 2018).

TB-500 → G-Actin Sequestration / ILK / Cell Migration: TB-500 (Ac-LKKTETQ, residues 17–23 of Thymosin Beta-4) sequesters G-actin monomers in a 1:1 stoichiometric complex via the WH2 (Wiskott-Aldrich Syndrome Homology 2) actin-binding domain. This G-actin sequestration maintains the cytoplasmic pool of unpolymerised actin available for rapid filament nucleation at the leading edge of migrating cells, directly driving directional cell migration in fibroblasts, keratinocytes, and endothelial cells. Bock-Marquette et al. (2004, Nature, PMID 15558062) documented Tβ4 activating ILK → Akt phosphorylation → anti-apoptotic signalling in a murine cardiac repair model. In angiogenesis research, TB-500 drives endothelial cell chemotaxis as a potent chemoattractant via actin dynamic modulation, complementing BPC-157's VEGFR2-dependent endothelial proliferation mechanism.

What are the Potential Research Applications of GLOW Blend?

• Multi-pathway angiogenesis research: BPC-157 activates VEGFR2-Akt-eNOS; GHK-Cu upregulates VEGF and bFGF gene expression in fibroblast models; TB-500 drives endothelial cell chemotaxis via actin dynamics. Three mechanistically non-overlapping angiogenic pathways in one formulation, investigated in tube formation, scratch assay, and aortic ring sprouting model systems.
• Extracellular matrix remodelling investigation: GHK-Cu modulates type I/III collagen synthesis, proteoglycan deposition, and MMP-2/TIMP balance in fibroblast models. TB-500 promotes organized fibroblast migration and collagen deposition. BPC-157 supports granulation tissue formation markers in rodent wound models.
• Cell migration and cytoskeletal biology: TB-500's G-actin sequestration and GHK-Cu's ILK pathway activation regulate cell migration through distinct cytoskeletal mechanisms. GLOW Blend provides a tool for investigating how actin dynamics and copper-mediated integrin signalling independently and jointly regulate directional cell migration in wound closure and transwell migration model systems.
• Cytoprotective pathway investigation: In preclinical organ injury models (gastrointestinal, hepatic, cardiac), BPC-157's VEGFR2/NO/FAK cytoprotective profile has been investigated across multiple organ system contexts. GHK-Cu's antioxidant gene regulation and NF-κB suppression provide complementary cytoprotective pathway coverage.

What are the Potential Side Effects of GLOW Blend?

• No organ toxicity documented for any of the three components at research concentrations in published preclinical literature
• GHK-Cu contains Cu²⁺; at concentrations exceeding the physiological nanomolar range, excess copper may generate oxidative stress signals in cell model systems - copper homeostasis should be monitored in extended cell model experiments
• BPC-157 is under active FDA PCAC review; regulatory status may change
• No controlled toxicity data exist for this specific triple-peptide blend formulation. Data remains limited and findings are not consistent across all preclinical model systems.

Risk & Handling

Handling Precautions

• Trained laboratory personnel only. PPE: nitrile gloves, laboratory coat, eye protection.
• Reconstitute under aseptic conditions with sterile or bacteriostatic water. All three components are co-lyophilized - reconstitute as a blend for combination studies or separately if individual component isolation is required.

Exposure Risks

• Risk Tier: MODERATE - GHK-Cu contains Cu²⁺ which at supraphysiological concentrations may generate oxidative stress in cell models. No human safety data established for this specific triple-peptide blend formulation.
• BPC-157 is under FDA PCAC review. Researchers should monitor regulatory updates regarding BPC-157 bulk substance status.

Storage

• Store at −20°C, sealed, protected from light. Reconstitute with sterile or bacteriostatic water under aseptic conditions. Do not re-freeze the reconstituted solution.

FAQs

Are there any components in GLOW Blend SARMs?

No. None of BPC-157, GHK-Cu, or TB-500 interact with androgen receptors. BPC-157: VEGFR2/NO/FAK pathways. GHK-Cu: copper-mediated integrin/MMP signalling. TB-500: actin sequestration/ILK activation. None qualifies as a SARM.

Why is GHK-Cu at a higher dose (50mg) compared to BPC-157 and TB-500 (10mg each)?

GHK-Cu is investigated at nanomolar to low micromolar concentrations in cell model research (effective range: 1–10 nM for fibroblast collagen stimulation). The higher mass per vial reflects the fact that more material is needed to prepare research-standard working solutions at these concentrations for high-volume experiments compared to BPC-157 and TB-500, which are typically investigated in lower-volume assay systems.

What is BPC-157's current FDA regulatory status?

BPC-157 is under FDA PCAC review for potential designation as a prohibited bulk compounding substance. It is not FDA-approved for any indication. This vial is a research reagent only. Researchers should monitor FDA PCAC announcements for updates.

What is the relationship between TB-500 and Thymosin Beta-4?

TB-500 is the synthetic heptapeptide Ac-LKKTETQ corresponding to residues 17–23 (the G-actin sequestering WH2 domain) of the full 43-amino acid Thymosin Beta-4 (Tβ4) protein. TB-500 retains core actin-binding and cell migration activity. Most primary published data are for full-length Tβ4; the TB-500 fragment-specific data base is narrower and researchers must distinguish between fragment and full-length parent compound data in study design.

Storage conditions?

Store lyophilized at −20°C, sealed, light-protected. Reconstitute with sterile or bacteriostatic water under aseptic conditions. Do not re-freeze the reconstituted solution.

References

Kennedy DO. B Vitamins and the Brain: Mechanisms, Dose and Efficacy — A Review. Nutrients. 2016;8(2):68. PMID 26828517. (Covers B-vitamin cofactor roles in CNS and metabolism — directly relevant to the multi-cofactor blend rationale)

Stover PJ. Physiology of folate and vitamin B12 in health and disease. Nutr Rev. 2004;62(6 Pt 2):S3–12. PMID 15298452. (Covers folic acid one-carbon metabolism and B12-folate intersection — relevant to HHB's folate + B12 pathway mechanisms)

Disclaimer: GLOW Blend (BPC-157 + GHK-Cu + TB-500) is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co